Potentiation of neuromuscular weakness in infant botulism by aminoglycosides.
A retrospective study of ten patients with infant botulism who received gentamicin or kanamycin suggests that aminoglycoside antibiotics potentiate muscular weakness and precipitate respiratory failure as late as 27 days after onset of the disease. Although it is difficult to separate progression of the disease from the effects of antibiotics, the rapidity of deterioration following aminoglycoside treatment and the rapidity of recovery following cessation of aminoglycoside therapy is highly suggestive. A review of five patients who received only penicillin or a semisynthetic derivative of penicillin did not reveal any temporal deterioration with onset of penicillin therapy or improvement with cessation of penicillin therapy.
D000667:Ampicillin / Q000627:therapeutic use; D001906:Botulism / Q000150:complications / Q000188:drug therapy*; D002701:Chloramphenicol / Q000627:therapeutic use; D003023:Cloxacillin / Q000627:therapeutic use; D004357:Drug Synergism; D005839:Gentamicins / Q000009:adverse effects*; D006801:Humans; D007223:Infant; D007231:Infant, Newborn; D007232:Infant, Newborn, Diseases / Q000188:drug therapy; D007612:Kanamycin / Q000009:adverse effects*; D008297:Male; D009123:Muscle Hypotonia / Q000139:chemically induced* / Q000209:etiology; D012131:Respiratory Insufficiency / Q000139:chemically induced
D005839:Gentamicins; D007612:Kanamycin; D002701:Chloramphenicol; D000667:Ampicillin; D003023:Cloxacillin